Director Richard Pilnik to retire from DiaMedica board at 2025 AGM

DiaMedica Therapeutics Inc.

Richard Pilnik, director for over 15 years, will retire and not stand for re-election at the 2025 AGM, effective May 15, 2025.
His decision is not due to any disagreement with the company on operations, policies, or practices.
Chairman role already transitioned to James Parsons; board also recently added Daniel O'Connor as new director.
Board to re-evaluate committee composition and chair roles after Pilnik's departure for seamless transition.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Richard Pilnik

Director

DMAC · DiaMedica Therapeutics Inc.

Effective: 2025-05-15
Filed: March 6, 2025, 6:59 PM ET

On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Pilnik departed as Director at DiaMedica Therapeutics Inc..

Action: retire
Role: Director

Exact text from the filing

On February 28, 2025, Richard Pilnik, who has been a member of the Board of Directors (the “Board”) of DiaMedica Therapeutics Inc. (the “Company”), for over 15 years, informed the Company of his decision to retire and not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”).

View on SEC.gov

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-006379

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.